MedTrace Logo

BAY 0 9867 Cipro Pediatric Use Study (QUIP)

NCT00761462 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1029

Last updated 2015-07-31

Study results available
· View outcomes & findings →

Summary

Objective and subjective musculoskeletal evaluations will be performed to determine differences in the ciprofloxacin versus non-quinolone treated pediatric patients so that we can tell what the natural occurrence of such musculoskeletal conditions is in the general pediatric population.

Conditions

Interventions

DRUG

Ciprofloxacin

Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label

DRUG

Non-quinolone antibiotic

Common used dose and route

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761462 on ClinicalTrials.gov